Aug 6, 2008 by Brian LawlerExelixis Gets Ready to Partner UpThe company is looking for some friends to help develop its drugs.
Aug 5, 2008 by Brian LawlerAn ImClone Deal Will Get DoneDespite his tough talk, Icahn will likely complete a buyout of ImClone.
Aug 4, 2008 by Brian LawlerVertex on the Verge of VictoryFinancials, schminancials -- clinical trial results are where it's at.
Aug 1, 2008 by Brian LawlerElan Becomes a Bad News BuyThe Fool's perpetual Elan bear has turned bullish at these prices.
Aug 1, 2008 by Brian LawlerHoly Moley, CV Therapeutics!It's hard to argue with across-the-board success.
Aug 1, 2008 by Brian LawlerIs $60 a Share Enough for ImClone?Another big name in biotech could be on the brink of being taken out.
Jul 31, 2008 by Brian LawlerExamining Elan's Ups and DownsWas the pharmaceutical's news as bad as investors treated it?
Jul 28, 2008 by Brian LawlerAmgen's Bone-Building BoostThe drugmaker gets good news about a top pipeline compound.
Jul 25, 2008 by Brian LawlerPlace Your Biotech BetsNext week could bring big-time winners and losers.
Jul 24, 2008 by Brian LawlerWill Pfizer Pfizzle?The drugmaker posts strong earnings, but the good times may not last.
Jul 23, 2008 by Brian LawlerNo Picking at BiogenThere’s not much to complain about with the company’s second-quarter numbers.
Jul 22, 2008 by Brian LawlerAnxiously Awaiting ExelixisPivotal clinical trial results for a top drug are finally within sight.
Jul 21, 2008 by Brian LawlerRoche Wants to Buy Genentech -- AgainWhat's behind the pharmaceutical's latest offer?
Jul 21, 2008 by Brian LawlerAmgen Rolls the DiceThe Food and Drug Administration's impending ruling will determine the drugmaker's near-term fate.
Jul 18, 2008 by Brian LawlerStill Liking Gilead, Warts and AllDon't look past a few issues, even though Gilead still has a bright future.
Jul 16, 2008 by Brian LawlerA Big Move From ViroPharmaIt picks up an asset that's more than half its size.
Jul 15, 2008 by Brian LawlerGenentech Needs More Profit PowerAnother fine quarter of sales, but what about net earnings?
Jul 10, 2008 by Brian LawlerSeattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.
Jul 10, 2008 by Brian LawlerLilly Targets a Tiny PrizeAs drugmakers go, this acquisition's a value meal.
